Cross-reference to Form 20-F
The information in this document that is referenced on this page is included in AstraZeneca's Form 20-F for 2009 (2009 Form 20-F) and is filed with the SEC. The 2009 Form 20-F is the only document intended to be incorporated by reference into any filings by AstraZeneca under the Securities Act of 1933, as amended. References to major headings include all information under such major headings, including subheadings. References to subheadings include only the information contained under such subheadings. Graphs are not included unless specifically identified. The 2009 Form 20-F has not been approved or disapproved by the SEC, nor has the SEC passed comment upon the accuracy or adequacy of the 2009 Form 20-F. The 2009 Form 20-F filed with the SEC may contain modified information and may be updated from time to time.
3. Key Information
| A. | Selected financial data |
| Financial highlights | |
| Group Financial Record | |
| Additional Information - Shareholder Information | |
| D. | Risk factors |
| Directors' Report - Principal risks and uncertainties |
4. Information on the Company
5. Operating and Financial Review and Prospects
6. Directors, Senior Management and Employees
7. Major Shareholders and Related Party Transactions
| A. | Major shareholders |
| Additional Information - Major shareholdings | |
| B. | Related party transactions |
| Additional Information - Related party transactions | |
| Note 27 - Statutory and other information - Related party transactions |
8. Financial Information
| A. | Consolidated statements and other financial information |
| Financial Review - Dividend and share re‑purchases | |
| Directors' Report - Distributions to shareholders and dividends for 2009 | |
| Financial Statements (excluding Directors' responsibilities described in the Preparation of the Financial Statements and Directors' Responsibilities and Directors' Responsibilities for, and Report on, Internal Control over Financial Reporting sections and Auditor's opinion described in the Independent Auditor's Report to the Members of AstraZeneca PLC section) | |
| Additional Information - Shareholder Information | |
| B. | Significant changes |
| Note 27 - Statutory and other information |
9. The Offer and Listing
| A4. | Price history of listed stock |
| Additional Information - Shareholder information | |
| C. | Markets |
| Additional Information - Shareholder information |
10. Additional Information
| B. | Memorandum and Articles of Association |
| Additional Information - Articles | |
| D. | Exchange controls and other limitations affecting security holders |
| Additional Information - Exchange controls and other limitations affecting security holders | |
| E. | Taxation |
| Financial Review - Taxation | |
| Additional Information - Taxation for US residents | |
| Additional Information - UK and US income taxation of dividends | |
| Additional Information - Taxation on capital gains | |
| Additional Information - Passive Foreign Investment Company (PFIC) rules | |
| Additional Information - UK inheritance tax | |
| Additional Information - UK stamp duty reserve tax and stamp duty | |
| H. | Documents on display |
| Additional Information - Documents on display |
11. Quantitative and Qualitative Disclosures about Market Risk
| Financial Review - Financial risk management | |
| Note 15 - Financial risk management objectives and policies | |
| Note 16 - Financial instruments |
15. Controls and Procedures
16. [Reserved]
| A. | Audit Committee financial expert |
| Directors' Report - Audit Committee | |
| Directors' Report - Board Committee membership | |
| B. | Code of ethics |
| Directors' Report - Code of Conduct | |
| C. | Principal accountant fees and services |
| Directors' Report - Audit Committee | |
| Note 27 - Statutory and other information | |
| E. | Purchases of equity securities by the issuer and affiliated purchasers |
| Note 20 - Share capital of the Company - Share re-purchases | |
| G. | Corporate governance |
| Directors' Report - Principal corporate governance requirements |
18. Financial Statements
| Financial Statements (excluding Directors' responsibilities described in the Preparation of the Financial Statements and Directors' Responsibilities and Directors' Responsibilities for, and Report on, Internal Control over Financial Reporting sections and Auditor's opinion described in the Independent Auditor's Report to the Members of AstraZeneca PLC section) |
